We hereby inform you that AAHL Ireland, Stepdown wholly owned subsidiary of the Company has entered into a Binding agreement today i.e. June 08, 2026 for acquisition of 100% shareholding ....
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 08 Jun 2026, 12:40 PM IST · BSE ID: fb7b1411-8d31-440d-b322-814d65b6b216
View Original BSE Filing (PDF)
💡
In Simple Terms
Viyash Scientific's subsidiary is buying an Italian animal health products company for EUR 16.975 million.
🤖 AI Summary
- Viyash Scientific's subsidiary, AAHL Ireland, to acquire 100% of BioForLife Italia s.r.l. for EUR 16.975 million.
- The acquisition includes EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration.
- BioForLife Italia s.r.l. is engaged in marketing and distribution of animal health products, with CY 2025 sales of approximately EUR 9.0 million.
- The acquisition aims to expand Viyash's presence in Italy's companion animal segment.
- Initial closing is expected within three months, subject to conditions precedent and regulatory approvals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Consideration
EUR 16.975 million
Consideration Payable at Closing
EUR 15.0 million
Deferred Consideration
EUR 1.975 million
BioForLife Italia s.r.l. CY 2025 Annual Sales
EUR 9.0 million
BioForLife Italia s.r.l. CY 2024 Annual Sales
8.3 Mn €
BioForLife Italia s.r.l. CY 2023 Annual Sales
7.1 Mn €
🏢 How This Affects the Company
This acquisition will strengthen and scale Viyash Scientific's presence in Italy within the companion animal segment, enhancing its front-end platform, customer reach, and product capabilities.
The transaction involves an aggregate cash consideration of EUR 16.975 million, impacting the company's cash reserves and balance sheet for the acquisition payment.
The acquisition integrates BioForLife Italia's marketing and distribution network for animal health products into Viyash Scientific's operations, primarily in Italy.
The transaction is subject to governmental and regulatory approvals, including notification under Italian Golden Power Laws, introducing regulatory completion risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders.
👤
Who Is Affected
Shareholders are affected by Viyash Scientific's strategic decision to expand its international footprint and commit EUR 16.975 million towards this acquisition.
🔍
Management Signal
This decision indicates management's intent to pursue inorganic growth and strengthen the company's market position in the animal health segment in Europe.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Announcement of the initial closing for the BioForLife Italia s.r.l. acquisition.
Disclosure of any updates regarding regulatory approvals under Italian Golden Power Laws.
Details on the settlement of the EUR 1.975 million deferred consideration.
MEDIUM RISK
The acquisition is subject to regulatory approvals and conditions precedent, indicating execution risk.
💡 Investor Takeaway
Viyash Scientific's step-down subsidiary entered a binding agreement to acquire 100% of BioForLife Italia for EUR 16.975 million, including EUR 15.0 million at closing. The target entity reported CY 2025 annual sales of approximately EUR 9.0 million.
⚖️ Strengths & Concerns
✅ Positives
- Acquisition of 100% shareholding in BioForLife Italia s.r.l. provides full control and integration into Viyash Scientific's operations.
- BioForLife Italia s.r.l. reported annual sales of approximately EUR 9.0 million for CY 2025, indicating an established revenue stream.
⚠️ Concerns
- The aggregate consideration of EUR 16.975 million is a significant cash outlay for the company, impacting liquidity.
- Completion of the acquisition is subject to fulfilment of applicable conditions precedent and statutory/regulatory approvals, which introduce execution uncertainty.
❓ Frequently Asked Questions
What is the total consideration for Viyash Scientific's acquisition of BioForLife Italia?
The aggregate consideration for the acquisition of BioForLife Italia s.r.l. by Viyash Scientific's subsidiary is EUR 16.975 million.
How is the payment structured for the BioForLife Italia acquisition?
The payment is structured with EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration.
What were the annual sales of BioForLife Italia s.r.l. for Calendar Year 2025?
BioForLife Italia s.r.l. reported annual sales of approximately EUR 9.0 million for Calendar Year 2025.
What is the purpose of Viyash Scientific's acquisition of BioForLife Italia?
The acquisition is intended to strengthen and scale Viyash Scientific's presence in Italy's companion animal segment through an established front-end platform, customer reach, and product capabilities.
What is the indicative time period for completion of the BioForLife Italia acquisition?
Initial closing of the acquisition is expected within 3 months from the execution of the binding agreement, subject to fulfilment of conditions precedent.
Questions based on this BSE filing only. For information purposes.